Breakthrough Claims Are Routine as 30.3% of Research Records Claim a First but Only 17.4% of Those State Two or More Rigour Signals

InnoDexis has published its latest Innovation Intelligence Report covering breakthroughs and novel approaches, analyzing 3,581 research records, of which 1,085 claim a first, and 4,840 corporate records, of which 267 make a first claim, during the 1–29 September 2026 observation window. The report reveals that novelty is claimed often and evidenced rarely: 30.3 percent of research records claim a first, only 17.4 percent of those state two or more rigour signals, and the rarest class, 24 null results, is the most rigorous at 1.21 signals.

Key Findings

First claims are common and rarely evidenced. Of 1,085 research first claims, 30.3 percent of records, only 189, 17.4 percent, state two or more rigour signals, and first claims are only slightly more ready, 12.9 percent High against 10.7 percent, and barely more rigorous, 0.78 signals against 0.73.

Corporate first claims carry momentum, especially with a figure. The 267 first claims score 5.74 and carry 24.3 percent High momentum against 4.97 and 11.0 percent for the rest, rising to 36.7 percent with a published figure against 18.1 percent without.

Discovery is far from use. New mechanisms or discoveries, 1,085 records, are 6.0 percent High readiness and new materials and molecules, 171 records, 2.3 percent, while records and superlatives, 54 records, are the most ready at 22.2 percent with 59.3 percent high scientific depth.

Null results are rare and rigorous. Only 24 records are primarily contrarian or null results, including the EASD semaglutide–pancreatic cancer result across 97,464 users, a Phase III trial showing local consolidative therapy fails to extend survival and the ORBEX trial showing OM-85 fails to prevent paediatric asthma, and they average 1.21 rigour signals.

Field and national cultures differ. Space claims firsts in 42.6 percent of records, robotics 36.5 percent and semiconductors 34.3 percent against 21.8 percent in connectivity, and Switzerland leads at 42.2 percent and Japan 39.2 percent against 26.0 percent for Germany and 26.2 percent for China. Germany’s lower rate reflects its applied, institute-heavy mix.

Strategic Insight and Trend Analysis

The defining structural finding is novelty inflation: nearly a third of research records and one in twenty corporate records claim a first, and the claim carries a modest readiness and momentum premium that becomes large only when backed by figures. The word ‘first’ is an invitation to check, not evidence, and many research firsts are local, the first study in a region or the first map of a place, rather than global. Momentum and the presence of figures are both analyst-assigned, so the premium is a strong correlation, not proof.

Evidence, not novelty, is what travels. The evidenced firsts are clinical, including MD Anderson’s first randomised Phase 3 of GammaTile, Mayo Clinic’s first RCT of fractionated radiosurgery with 242 patients and a 31 percent lower local-recurrence risk, and the Medical University of Vienna’s randomised evidence on postoperative radiotherapy, while first claims account for 43 of 131 company formations, so novelty language does track commercial intent.

The most useful novelty may be negative. Null results are under-announced relative to their evidential value, and the stream’s highest-momentum corporate categories are investment and funding signals at 37.9 percent High and clinical-trial signals at 34.9 percent, against 10.5 percent for the 1,973 product-breakthrough signals. Replication and validation, named in 499 research-gap entries, is the direct remedy for unevidenced firsts.

Global and Industry Implications

For corporates and R&D teams, make first claims checkable by publishing a figure, since 36.7 percent of figure-backed first claims carry High momentum against 18.1 percent, and use null results to stop spending, including the semaglutide safety result, local consolidative therapy and OM-85. Licensing evidenced academic firsts, licensing record-setting data products such as IMBIE’s polar ice record of 11.3 trillion tonnes lost, and monitoring replication of competitors’ firsts are the named scouting moves. Mechanism and materials discoveries, at 6.0 and 2.3 percent High readiness, are options for five to ten years.

For investors and capital allocators, novelty plus evidence predicts momentum while novelty alone barely does, so due diligence should ask what the first is compared with and whether it is global or local. Named opportunities include clinical firsts at MD Anderson, Mayo Clinic and Vienna, Insilico Medicine’s first Phase III of a generative-AI drug, and device firsts with figures at Bestzyme and Frore Systems.

For policymakers and national innovation bodies, negative evidence is a public good, so the priorities are funding replication of high-profile firsts, supporting publication of null results and requiring comparators in publicly funded announcements. Replication grants and trial-results reporting are the named levers.

InnoDexis Statement

“Novelty is claimed generously and evidenced sparingly — a first claim pays when it carries a number, and the most useful novelty of the month may be the rigorous null result that tells readers what not to do,” noted InnoDexis in its latest intelligence report.

Conclusion

Because novelty classes describe the type of claim and not its truth, rigour reflects what summaries state, momentum is analyst-assigned and one month supports no trend, the findings are cross-sectional. The signals to watch are whether the evidenced share of first claims rises above 25 percent, whether an independent group replicates a first claim, whether a corporate first claim is backed by peer-reviewed data, and whether large trials report further null results. The complete Breakthroughs & Novel Approaches Report September 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.